WaveMan
WaveMan · Company
CUE · Cue Biopharma, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CUE Cue Biopharma (CUE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001645460
Quote by TradingView
Activist 13DForm 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
17
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $0 priced

What the filings say about CUE

Insiders, 180 days
-$2.4M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.7M
4 notices
Activist stakes (13D), 180 days
1 filing
Largest: 6.2% of the class

Cue Biopharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Cue Biopharma, Inc. insiders sold a net $2.4M of stock across 35 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Lin Shao-Lee
Chief Executive Officer
SELL
2026-10-14 SECtraded 2026-10-12
10,000
$275.0K
-0.1%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 13, 2026.
  • The trade is 1.4% of the 695,995 shares held after it.
  • 2 other insiders sold within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lin Shao-Lee sold about $275.0K of CUE on Oct 12, 2026; 2 other insiders sold within 30 days and 17 funds added in the latest 13F quarter.
Lin Shao-Lee
Chief Executive Officer
SELL
2026-10-14 SECtraded 2026-10-12
1,087
$30.5K
-0.1%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 13, 2026.
  • The trade is 0.2% of the 694,908 shares held after it.
  • 2 other insiders sold within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lin Shao-Lee sold about $30.5K of CUE on Oct 12, 2026; 2 other insiders sold within 30 days and 17 funds added in the latest 13F quarter.
Meluzio Michael Vincent
VP, Prin. Accounting Officer
SELL
2026-10-14 SECtraded 2026-10-12
1,144
$32.1K
-0.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 13, 2026.
  • The trade is 2.4% of the 47,817 shares held after it.
  • 2 other insiders sold within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, Prin. Accounting Officer Meluzio Michael Vincent sold about $32.1K of CUE on Oct 12, 2026; 2 other insiders sold within 30 days and 17 funds added in the latest 13F quarter.
Ray Sumita
Chief Legal Compliance Officer
SELL
2026-10-14 SECtraded 2026-10-12
1,844
$51.7K
-0.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 13, 2026.
  • The trade is 1.6% of the 116,701 shares held after it.
  • 2 other insiders sold within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Compliance Officer Ray Sumita sold about $51.7K of CUE on Oct 12, 2026; 2 other insiders sold within 30 days and 17 funds added in the latest 13F quarter.
Lin Shao-Lee
Chief Executive Officer
SELL
2026-08-14 SECtraded 2026-08-13
5,423
$147.5K
-32.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 12, 2026.
  • The trade is 0.8% of the 718,830 shares held after it.
  • 2 other insiders sold within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lin Shao-Lee sold about $147.5K of CUE on Aug 13, 2026; 2 other insiders sold within 30 days and 17 funds added in the latest 13F quarter.
35 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 30 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$2.4M over 180 days
-$2.4M over 90 days
below 72% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
17 funds bought in last quarter
below 71% of Pharma & Biotech
Revenue
+195.7% year over year
more than 89% of Pharma & Biotech
Margin
-96.9% net margin
below 57% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
11.0% of the float short (float per yahoo 2026-10-26) · 1.1 days to cover · settled 2026-09-30
more than 70% of Pharma & Biotech
The situation: each line is one rule over one dataset
Shao-Lee Lin disclosed a 5%+ stake (6.2%) in the last six months.
What changed in the last 30 days
Oct 14Chief Executive Officer Lin Shao-Lee sold $305.5K (Oct 12)
Oct 14Chief Legal Compliance Officer Ray Sumita sold $51.7K (Oct 12)
Oct 14VP, Prin. Accounting Officer Meluzio Michael Vincent sold $32.1K (Oct 12)
Oct 13Officer Shao-Lee Lin filed to sell $305.5K by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 13Officer Sumita Ray filed to sell $51.7K by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch CUE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-18.7%12M
-77%-30%+18%+65%2025-102025-122026-022026-042026-062026-082026-10 2026-08-12 · Lin Shao-Lee sold $923.7K2026-08-13 · Lin Shao-Lee sold $308.4K2026-10-12 · Lin Shao-Lee sold $275.0K2026-08-13 · Ray Sumita sold $195.5K2026-08-12 · Lin Shao-Lee sold $160.3K2026-08-13 · Lin Shao-Lee sold $147.5K2026-08-13 · Meluzio Michael Vincent sold $124.6K2026-08-13 · Ray Sumita sold $70.0K2026-08-13 · Lin Shao-Lee sold $66.8K2026-10-12 · Ray Sumita sold $51.7K2026-08-13 · Meluzio Michael Vincent sold $44.6K2026-10-12 · Meluzio Michael Vincent sold $32.1K2026-10-12 · Lin Shao-Lee sold $30.5K2025-12-30 · Sarraf Pasha bought $27.8K2025-12-30 · Sarraf Pasha bought $24.2K2025-12-30 · Sarraf Pasha bought $23.2K2025-12-30 · Sarraf Pasha bought $23.1K2025-12-30 · Sarraf Pasha bought $1.3K2026-08-13 · Ray Sumita sold $1252026-08-13 · Meluzio Michael Vincent sold $932026-08-21 · Shao-Lee Lin filed a 5%+ stake (6.2%)2026-10-13 · Sumita Ray filed to sell $51.7K2026-10-13 · Shao-Lee Lin filed to sell $305.5K2026-08-14 · Shao-Lee Lin filed to sell $1.1M2026-08-13 · Sumita Ray filed to sell $266.1K
Insider buyInsider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CUE: institutional holders (13F)

13F holdings, latest reported quarter
Bleichroeder LP
370,682 sh
$11.7M
Driehaus Capital Management LLC
292,144 sh
$9.2M
VANGUARD CAPITAL MANAGEMENT LLC
161,700 sh
$5.1M
Ikarian Capital, LLC
104,364 sh
$3.3M
Tetragon Partners GP Ltd
93,819 sh
$3.0M

Congress trades in CUE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Shao-Lee Lin
Activist 13D · 2026-08-21
6.2%

CUE planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Sumita Ray
Filed 2026-10-13
$51.7K
Shao-Lee Lin
Filed 2026-10-13
$305.5K
Shao-Lee Lin
Filed 2026-08-14
$1.1M
Sumita Ray
Filed 2026-08-13
$266.1K

CUE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$351.2K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$23.6K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$1.5M position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$351.1K position · as of 2026-05-31
0.0%
Dimensional U.S. Small Cap ETF
$48.7K position · as of 2026-07-31
0.0%
Avantis U.S. Small Cap Equity ETF
$6.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $2.4M sold by insiders over 180 days, 17 funds added last quarter, $1.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CUE financials

Revenue growth
+195.7%
XBRL, annual
Net margin
-96.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$37.7M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-435.8%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$50.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.04x
long-term 2024-12-31 (18 months older than the period end) plus current 2025-03-31 (15 months older than the period end); equity 2026-06-30
Cash flow to debt
-500.46x
TTM operating cash flow over long-term 2024-12-31 (18 months older than the period end) plus current 2025-03-31 (15 months older than the period end)
Return on equity
-1,603%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-459.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-637.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$118.3M
market value at close 2026-10-23 on 2026-08-12 shares, plus long-term 2024-12-31 (18 months older than the period end) plus current 2025-03-31 (15 months older than the period end), minus cash 2026-06-30
FCF yield
-37.0%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$27.5M$9.3M$5.5M$1.2M
Operating income-$26.6M-$41.5M-$52.1M-$53.2M
Net income-$26.6M-$40.7M-$50.7M-$53.0M
EPS (diluted)-0.28-0.72-1.11-1.49
Operating cash flow-$21.7M-$36.3M-$40.0M-$41.8M
Cash$27.1M$22.5M$48.5M$51.6M
Long-term debtn/a$0$4.2M$8.0M
Buybacksn/an/a$0$200.0K
SEC XBRL, fiscal years, as known on 2026-10-27

CUE Stock Sonar score 6/7 axes

Find similar shapesCompare

CUE ranks highest on growth (72nd percentile) and financial health (33rd), and lowest on profitability (3rd), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
3
Inputs
  • Return on equity-1603% · 3 pct, sector of 545
  • Return on assets-459.6% · 5 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-637.7% · 2 pct, sector of 576
Financial health
33
Inputs
  • Debt to equity0.04x · 64 pct, sector of 352
  • Cash flow to debt-500.46x · 2 pct, sector of 371
Growth
72
Inputs
  • Revenue growth, YoY+195.7% · 89 pct, sector of 505
  • Backlog growth, YoY+0.0% · 54 pct, sector of 40
Insider conviction
13
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.4M · 27 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
29
Inputs
  • Funds adding, latest quarter17 · 29 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
32
Inputs
  • Short interest, % of float+11.0% · 37 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+15.9% · 27 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CUE filings, in plain words

Are Cue Biopharma insiders buying or selling CUE?

In the 180 days to 2026-10-27, Cue Biopharma insiders were net sellers, a net $2.4M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of CUE?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $1.7M of stock; the latest, by Sumita Ray, was filed 2026-10-13.

Read the full summary

In the 180 days to 2026-10-27, Cue Biopharma insiders were net sellers of CUE, a net $2.4M across purchases and sales reported on Form 4 by 3 sellers. None of the 15 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $1.7M of stock. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 6.2% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies